Equities
Health CarePharmaceuticals & Biotechnology
  • Price (GBX)2,018.00
  • Today's Change-31.00 / -1.51%
  • Shares traded603.37k
  • 1 Year change-11.49%
  • Beta1.2667
Data delayed at least 20 minutes, as of Sep 30 2016 17:01 BST.
More ▼

Key statistics

On Friday, Hikma Pharmaceuticals PLC (HIK:LSE) closed at 2,018.00, 28.13% above the 52 week low of 1,575.00 set on Mar 16, 2016.
52-week range
Today
1,575.00Mar 16 20162,703.00Aug 02 2016
Markit short selling activity
Low
Med
High
Open2,041.00
High2,044.00
Low2,004.00
Bid2,018.00
Offer2,289.00
Previous close2,049.00
Average volume483.47k
Shares outstanding239.93m
Free float131.78m
P/E (TTM)31.22
Market cap4.84bn GBP
EPS (TTM)0.646 GBP
Annual div (IAD)23.00 GBX
Annual div yield (IAD)1.14%
Div ex-dateSep 01 2016
Div pay-dateSep 30 2016
Data delayed at least 20 minutes, as of Sep 30 2016 17:01 BST.
More ▼

Investors Chronicle View

The last IC recommendation on Hikma Pharmaceuticals PLC shares was Hold at 2,302.00 on 24 Aug 2016Read the full article

Board of Directors

1/9

Said Darwazah, Chairman and Chief executive officer

2/9

Mazen Darwazah, Executive Vice Chairman, President and CEO of MENA and Emerging Markets

3/9

Ali Al-Husry, Non-executive director

4/9

Robert Pickering, Senior Independent Director

5/9

Michael Ashton, Independent non-executive director

6/9

Breffni Byrne, Independent non-executive director

7/9

Ronald Goode, Independent non-executive director

8/9

Patrick Butler, Independent non-executive director

9/9

Dr. Pamela Kirby, Independent non-executive director

Investor Relations Contact

Susan Ringdal
Investor Relations Director
Email: susan.ringdal@hikma.uk.com
Tel: +44 (0) 20 7399 2760
Fax: +44 (0) 20 7399 2761

Hikma Pharmaceuticals PLC
13 Hanover Square
London W1S 1HW

© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.